Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- CEFP Members Call for Tapping CPTPP Trade Deal for Joint Drug Manufacturing
October 8, 2020
- Elite Team Working to Secure COVID-19 Vaccines; Indemnity to Be a Major Focus: Ex-MHLW Chief Medical Officer
October 8, 2020
- Japan’s COVID-19 Vaccine, Drug Development Lack Speed: Ex-MHLW Chief Medical Officer
October 7, 2020
- Health Minister Denies November Plan for Avigan's COVID-19 OK
October 7, 2020
- MHLW Panel Approves 18th Edition of Japanese Pharmacopoeia; 33 New Products Added
October 7, 2020
- Label Revisions Ordered for Takecab, 2 Other Drugs
October 7, 2020
- MHLW Lays Out Compliance Guidelines for Manufacturers; Introduction Planned in August 2021 under Amended PMD Law
October 6, 2020
- Scrap Income Limit for Fertility Treatment Subsidies: LDP Lawmakers
October 5, 2020
- MHLW to Draft Guidelines by Year-End on Use of Patient Registry Data in Drug Filing
October 5, 2020
- PMDA to Offer Free Consultations for COVID-19 Vaccines
October 2, 2020
- MHLW Bankrolls 3 Projects Aiming to Manufacture Key APIs, Raw Materials in Japan
October 2, 2020
- MHLW’s Review Division Head Stresses Evidence-Based Approval for Coronavirus Vaccines
October 1, 2020
- Metformin Cancer Risk Acceptable at 1 in 550,000 Patients: NIHS Assessment
October 1, 2020
- MHLW Submits FY2021 Budget, Personnel Requests
October 1, 2020
- Priority Shots for Seasonal Flu Begin for Elderly, Other High-Risk People
October 1, 2020
- Rotavirus Vaccines Now Covered by National Immunization Program
October 1, 2020
- Independent Monitoring Panel Kicks Off Discussions; MHLW-PMDA Collaboration, Ad Rules among Topics
September 30, 2020
- Kentaro Enomoto to Take Over Councilor Post for Health Insurance on October 1: MHLW
September 30, 2020
- MHLW Urges Healthcare Stakeholders to Comply with Distribution Guidelines Even in COVID-19 Outbreak
September 30, 2020
- MHLW Pharma Bureau Seeks 13 Billion Yen for FY2021, Eyes Vaccine Quality Assurance Guidance in COVID-19 Quota
September 29, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…